Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
NovoLog Mix 70/30
Overview
What is NovoLog Mix 70/30?
NOVOLOG MIX 70/30 (insulin aspart protamine and insulin aspart injection) is a human insulin analog suspension containing 70% insulin aspart protamine crystals and 30% soluble insulin aspart. NOVOLOG MIX 70/30 is a blood-glucose-lowering agent with an earlier onset and an intermediate duration of action. Insulin aspart is homologous with regular human insulin with the exception of a single substitution of the amino acid proline by aspartic acid in position B28, and is produced by recombinant DNA technology utilizing (baker’s yeast). Insulin aspart (NOVOLOG) has the empirical formula CHNOS and a molecular weight of 5825.8 Da.
Figure 1. Structural formula of insulin aspart
NOVOLOG MIX 70/30 is a uniform, white, sterile suspension that contains insulin aspart 100 units/mL.
Inactive ingredients are glycerol 16.0 mg/mL, phenol 1.50 mg/mL, metacresol 1.72 mg/mL, zinc 19.6 μg/mL, disodium hydrogen phosphate dihydrate 1.25 mg/mL, sodium chloride 0.877 mg/mL, and protamine sulfate 0.32 mg/mL. NOVOLOG MIX 70/30 has a pH of 7.20 - 7.44. Hydrochloric acid or sodium hydroxide may be added to adjust pH.
What does NovoLog Mix 70/30 look like?
What are the available doses of NovoLog Mix 70/30?
Injectable suspension: NOVOLOG MIX 70/30 is 100 units per mL (U-100), 70% insulin aspart protamine and 30% insulin aspart, is available as:
What should I talk to my health care provider before I take NovoLog Mix 70/30?
How should I use NovoLog Mix 70/30?
NOVOLOG MIX 70/30 is a mixture of insulin aspart protamine and insulin aspart indicated to improve glycemic control in patients with diabetes mellitus.
Limitations of Use:
•
(2.1).
•
2.1
•
(2.1)
•
(2.1)
•
2.1
•
2.1
•
(2.2)
•
2.2
•
2.2
•
2.2
What interacts with NovoLog Mix 70/30?
Sorry No Records found
What are the warnings of NovoLog Mix 70/30?
Sorry No Records found
What are the precautions of NovoLog Mix 70/30?
Sorry No Records found
What are the side effects of NovoLog Mix 70/30?
Sorry No records found
What should I look out for while using NovoLog Mix 70/30?
NOVOLOG MIX 70/30 is contraindicated
What might happen if I take too much NovoLog Mix 70/30?
Excess insulin administration may cause hypoglycemia and hypokalemia Mild episodes of hypoglycemia usually can be treated with oral glucose. Adjustments in drug dosage, meal patterns, or exercise, may be needed. More severe episodes with coma, seizure, or neurologic impairment may be treated with intramuscular/subcutaneous glucagon or concentrated intravenous glucose. Sustained carbohydrate intake and observation may be necessary because hypoglycemia may recur after apparent clinical recovery. Hypokalemia must be corrected appropriately.
How should I store and handle NovoLog Mix 70/30?
Store at 25°C (77° F); excursions permitted to 15-30 °C (59-86°F) [see USP Controlled Room Temperature].Product: 50090-2272NDC: 50090-2272-0 3 mL in a SYRINGE, PLASTIC Product: 50090-2273NDC: 50090-2273-0 10 mL in a VIAL, GLASS Product: 50090-2272NDC: 50090-2272-0 3 mL in a SYRINGE, PLASTIC Product: 50090-2273NDC: 50090-2273-0 10 mL in a VIAL, GLASS Product: 50090-2272NDC: 50090-2272-0 3 mL in a SYRINGE, PLASTIC Product: 50090-2273NDC: 50090-2273-0 10 mL in a VIAL, GLASS Product: 50090-2272NDC: 50090-2272-0 3 mL in a SYRINGE, PLASTIC Product: 50090-2273NDC: 50090-2273-0 10 mL in a VIAL, GLASS
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
The primary activity of insulin, including NOVOLOG MIX 70/30 is the regulation of glucose metabolism. Insulin and its analog lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis, and enhances protein synthesis.
Non-Clinical Toxicology
NOVOLOG MIX 70/30 is contraindicatedNOVOLOG MIX 70/30 FlexPen should never be shared between patients, even if the needle is changed. Patients using NOVOLOG MIX 70/30 vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens.
The following adverse reactions are also discussed elsewhere:
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).